Effects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT‐ACS Trial

BACKGROUND: The Effects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention for Non‐ST‐Segment Elevation Myocardial Infarction (SELECT‐ACS) trial suggested beneficial effects of inclacumab, a monoclonal antibody directed against P‐selectin, on peripr...

Descripción completa

Detalles Bibliográficos
Autores principales: Stähli, Barbara E., Gebhard, Catherine, Duchatelle, Valérie, Cournoyer, Daniel, Petroni, Thibaut, Tanguay, Jean‐François, Robb, Stephen, Mann, Jessica, Guertin, Marie‐Claude, Wright, R. Scott, L. L'Allier, Philippe, Tardif, Jean‐Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5210344/
https://www.ncbi.nlm.nih.gov/pubmed/27852589
http://dx.doi.org/10.1161/JAHA.116.004255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5210344/
https://www.ncbi.nlm.nih.gov/pubmed/27852589
http://dx.doi.org/10.1161/JAHA.116.004255

Ejemplares similares